Table 4

Clinicopathological features, p53 status, p53 protein accumulation, and c-FLIPL expression of six patients with ovarian carcinoma

Patient IDHistological type and gradep53 statusp53 accumulationc-FLIPL expression
WB*IHCWB*IHC
1Serous, G2Wild type+++
2Serous, G1Wild type++
3Serous, G3Wild type+++
4Serous, G3Exon 6, codon 195: ATC-ACC/Ile-Thr; exon 6, codon 213: CGA-CGG/polymorphism Arg-Arg+++++Weak
5Serous, G2Exon 7, codon 235: AAC-CAC/Asn−His; Exon 7, codon 236: TAC-CAC/Tyr-His++++
6Serous, G3Exon 5, codon 134: TTT-TCT/Phe-Ser; Exon 6, codon 213: CGA-CGG/polymorphism Arg-Arg++++
  • * Western blotting of total cellular lysates using mouse monoclonal antibody DO7 (Novocastra) for p53 and rabbit polyclonal antibody H-202 to FLIPL/S (Santa Cruz Biotechnology). For c-FLIPL detection, see legend for Fig. 8A<$REFLINK> .

  • Immunohistochemistry on paraffin-embedded sections using mouse monoclonal antibody DO7 (Novocastra) for p53 and goat polyclonal antibody C-19 to c-FLIPL.

  • Low reactivity in Western blotting due to low ratio of tumor cells vs. stromal tissue (see legend for Fig. 8B<$REFLINK> ).

  • Abbreviations: c-FLIPL, cellular FLICE-inhibitory protein long form; ID, identification; WB, Western blotting; IHC, immunohistochemical staining.